Efficacy and Safety of Nivolumab Combined with Daratumumab with or without Low-Dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma; Interim Analysis of the Phase 2 Nivo-Dara Study

Christie P. M. Verkleij; Monique C. Minnema; Okke de Weerdt; Patricia W. C. Bosman; Kristine A. Frerichs; Alexandra J. Croockewit; Saskia K. Klein; Gerard Bos; Tuna Mutis; Wouter J. Plattel; Ellen van der Spek; Annemiek Broyl; Pieter Sonneveld; Sonja Zweegman; Mark-David Levin; Niels W. C. J. Van de Donk

doi:https://doi.org/10.1182/blood-2019-124339

Efficacy and Safety of Nivolumab Combined with Daratumumab with or without Low-Dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma; Interim Analysis of the Phase 2 Nivo-Dara Study

Christie P. M. Verkleij, Monique C. Minnema, Okke de Weerdt, Patricia W. C. Bosman, Kristine A. Frerichs, Alexandra J. Croockewit, Saskia K. Klein, Gerard Bos, Tuna Mutis, Wouter J. Plattel, Ellen van der Spek, Annemiek Broyl, Pieter Sonneveld, Sonja Zweegman, Mark-David Levin, Niels W. C. J. Van de Donk

Research output: Contribution to journal › Meeting Abstract › Academic

Original language	English
Journal	Blood
Volume	134
DOIs	https://doi.org/10.1182/blood-2019-124339
Publication status	Published - 13 Nov 2019

Access to Document

https://doi.org/10.1182/blood-2019-124339

Cite this

Verkleij, C. P. M., Minnema, M. C., de Weerdt, O., Bosman, P. W. C., Frerichs, K. A., Croockewit, A. J., Klein, S. K., Bos, G., Mutis, T., Plattel, W. J., van der Spek, E., Broyl, A., Sonneveld, P., Zweegman, S., Levin, M.-D., & Van de Donk, N. W. C. J. (2019). Efficacy and Safety of Nivolumab Combined with Daratumumab with or without Low-Dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma; Interim Analysis of the Phase 2 Nivo-Dara Study. Blood, 134. https://doi.org/10.1182/blood-2019-124339

@article{2d66471c67bc4e7f9c0abaa093ae28c2,

title = "Efficacy and Safety of Nivolumab Combined with Daratumumab with or without Low-Dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma; Interim Analysis of the Phase 2 Nivo-Dara Study",

author = "Verkleij, {Christie P. M.} and Minnema, {Monique C.} and {de Weerdt}, Okke and Bosman, {Patricia W. C.} and Frerichs, {Kristine A.} and Croockewit, {Alexandra J.} and Klein, {Saskia K.} and Gerard Bos and Tuna Mutis and Plattel, {Wouter J.} and {van der Spek}, Ellen and Annemiek Broyl and Pieter Sonneveld and Sonja Zweegman and Mark-David Levin and {Van de Donk}, {Niels W. C. J.}",

year = "2019",

month = nov,

day = "13",

doi = "https://doi.org/10.1182/blood-2019-124339",

language = "English",

volume = "134",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

}

Verkleij, CPM, Minnema, MC, de Weerdt, O, Bosman, PWC, Frerichs, KA, Croockewit, AJ, Klein, SK, Bos, G, Mutis, T, Plattel, WJ, van der Spek, E, Broyl, A, Sonneveld, P, Zweegman, S, Levin, M-D & Van de Donk, NWCJ 2019, 'Efficacy and Safety of Nivolumab Combined with Daratumumab with or without Low-Dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma; Interim Analysis of the Phase 2 Nivo-Dara Study', Blood, vol. 134. https://doi.org/10.1182/blood-2019-124339

TY - JOUR

T1 - Efficacy and Safety of Nivolumab Combined with Daratumumab with or without Low-Dose Cyclophosphamide in Relapsed/Refractory Multiple Myeloma; Interim Analysis of the Phase 2 Nivo-Dara Study

AU - Verkleij, Christie P. M.

AU - Minnema, Monique C.

AU - de Weerdt, Okke

AU - Bosman, Patricia W. C.

AU - Frerichs, Kristine A.

AU - Croockewit, Alexandra J.

AU - Klein, Saskia K.

AU - Bos, Gerard

AU - Mutis, Tuna

AU - Plattel, Wouter J.

AU - van der Spek, Ellen

AU - Broyl, Annemiek

AU - Sonneveld, Pieter

AU - Zweegman, Sonja

AU - Levin, Mark-David

AU - Van de Donk, Niels W. C. J.

PY - 2019/11/13

Y1 - 2019/11/13

U2 - https://doi.org/10.1182/blood-2019-124339

DO - https://doi.org/10.1182/blood-2019-124339

M3 - Meeting Abstract

SN - 0006-4971

VL - 134

JO - Blood

JF - Blood

ER -